See more : Highland Transcend Partners I Corp. (HTPAF) Income Statement Analysis – Financial Results
Complete financial analysis of Wayland Group Corp. (MRRCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Wayland Group Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- York Timber Holdings Limited (YRK.JO) Income Statement Analysis – Financial Results
- Guangzhou Hangxin Aviation Technology Co., Ltd. (300424.SZ) Income Statement Analysis – Financial Results
- Glaston Oyj Abp (GLA1V.HE) Income Statement Analysis – Financial Results
- Hisamitsu Pharmaceutical Co., Inc. (HTSUF) Income Statement Analysis – Financial Results
- Best Agrolife Limited (BESTAGRO.NS) Income Statement Analysis – Financial Results
Wayland Group Corp. (MRRCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.waylandgroup.com
About Wayland Group Corp.
Wayland Group Corp. produces and sells medical and non-medical cannabis for cannabis patients and consumers in Canada and internationally. It offers a range of CBD, balanced, and THC strains under the Kiwi, Northern Harvest, High Tide, Lost at Seed, Solara C, Rare Dankness, and Maricann names. The company was founded in 2013 and is headquartered in Oakville, Canada. Wayland Group Corp. is a subsidiary of Maricann Group Inc.
| Metric | 2017 | 2016 | 2015 |
|---|---|---|---|
| Revenue | 2.48M | 3.06M | 0.00 |
| Cost of Revenue | 6.33M | 4.46M | 0.00 |
| Gross Profit | -3.85M | -1.39M | 0.00 |
| Gross Profit Ratio | -154.87% | -45.40% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 17.47M | 4.31M | 42.55K |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.47M | 4.31M | 42.55K |
| Cost & Expenses | 23.80M | 8.77M | 42.55K |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 36.92 | 340.29K | 35.99 |
| Depreciation & Amortization | 1.37M | 529.91K | 0.00 |
| EBITDA | -50.22M | -5.48M | -42.55K |
| EBITDA Ratio | -803.41% | -168.87% | 0.00% |
| Operating Income | -21.32M | -5.70M | -42.55K |
| Operating Income Ratio | -858.69% | -186.16% | 0.00% |
| Total Other Income/Expenses | -26.32M | -812.05K | -3.59M |
| Income Before Tax | -51.63M | -6.26M | -72.64K |
| Income Before Tax Ratio | -2,079.37% | -204.32% | 0.00% |
| Income Tax Expense | 5.28 | -2.90 | 0.00 |
| Net Income | -51.63M | -6.26M | -72.64K |
| Net Income Ratio | -2,079.37% | -204.32% | 0.00% |
| EPS | -0.75 | -0.17 | -0.01 |
| EPS Diluted | -0.75 | -0.17 | -0.01 |
| Weighted Avg Shares Out | 68.88M | 37.24M | 5.67M |
| Weighted Avg Shares Out (Dil) | 68.88M | 37.24M | 5.67M |
Source: https://incomestatements.info
Category: Stock Reports